🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the battle against superbug strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing globally, with figures suggesting over 82 million new cases annually. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, the spread of superbugs and the highly restricted treatment choices currently available.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Secure Authorization

One new antibiotic, also known as a brand name, was authorized by the US FDA in mid-December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts anticipate that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to see it through.

“This authorization signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Data and Global Access

As per results published in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The research included nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the rights to make available and distribute the drug in a wide range of developing nations.

Doctors treating patients have voiced positive views. Access to a single-dose, oral treatment such as this is seen as a "game-changer" for public health efforts. This is deemed essential to lessen the impact of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.